381 related articles for article (PubMed ID: 32638380)
1. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
2. MYC as a target for cancer treatment.
Duffy MJ; O'Grady S; Tang M; Crown J
Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 as a target for cancer treatment.
Duffy MJ; Synnott NC; Crown J
Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.
Soncini D; Caffa I; Patrone F; Ballestrero A; Nencioni A
Curr Cancer Drug Targets; 2012 May; 12(4):329-38. PubMed ID: 22385509
[TBL] [Abstract][Full Text] [Related]
5. Structural And Computational Perspectives of Selectively Targeting Mutant Proteins.
Coban MA; Fraga S; Caulfield TR
Curr Drug Discov Technol; 2021; 18(3):365-378. PubMed ID: 32160847
[TBL] [Abstract][Full Text] [Related]
6. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
8. Targeting p53 for the treatment of cancer.
Duffy MJ; Synnott NC; O'Grady S; Crown J
Semin Cancer Biol; 2022 Feb; 79():58-67. PubMed ID: 32741700
[TBL] [Abstract][Full Text] [Related]
9. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
10. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
11. A big step for MYC-targeted therapies.
Atibalentja DF; Deutzmann A; Felsher DW
Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
[TBL] [Abstract][Full Text] [Related]
12. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
13. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
Cui Y; Guo G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
[TBL] [Abstract][Full Text] [Related]
16. Early modification of c-myc, Ha-ras and p53 expressions by chemical carcinogens (DMBA, MNU).
Budán F; Varjas T; Nowrasteh G; Prantner I; Varga Z; Ember A; Cseh J; Gombos K; Pázsit E; Gobel G; Bauer M; Gracza T; Arany I; Perjési P; Ember I; Kiss I
In Vivo; 2009; 23(4):591-8. PubMed ID: 19567395
[TBL] [Abstract][Full Text] [Related]
17. The Research Progress of Direct KRAS G12C Mutation Inhibitors.
Yang A; Li M; Fang M
Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597
[No Abstract] [Full Text] [Related]
18. Taking on challenging targets: making MYC druggable.
Horiuchi D; Anderton B; Goga A
Am Soc Clin Oncol Educ Book; 2014; ():e497-502. PubMed ID: 24857145
[TBL] [Abstract][Full Text] [Related]
19. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
20. Drugging the Next Undruggable KRAS Allele-Gly12Asp.
Zheng Q; Peacock DM; Shokat KM
J Med Chem; 2022 Feb; 65(4):3119-3122. PubMed ID: 35167298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
